SCHEMBL8938754

SCHEMBL8938754

Nc1ccccc1N1CCc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
TP53 P04637 1/20 0.53
MAPK1 P28482 1/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
ROCK1 Q13464 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ADRA2C P18825 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
USP2 O75604 2/20 0.48
ALOX15 P16050 2/20 0.48
KEAP1 Q14145 1/20 0.48
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
SRD5A1 P18405 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
SIGMAR1 Q99720 1/20 0.46
HPGD P15428 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10547839 0.98 MAPK1 (0.51) LMNATP53MAPK1NPC1RAB9A
SCHEMBL10621398 0.88 ROCK1 (0.54) LMNATP53MAPK1NPC1RAB9A
SCHEMBL17179753 0.83 SMN1; SMN2 (0.48) LMNATP53MAPK1NPC1RAB9A
SCHEMBL10623802 0.81 MEN1 (0.46) LMNATP53MAPK1NPC1RAB9A
SCHEMBL10624233 0.81 SMN1; SMN2 (0.46) LMNATP53MAPK1NPC1RAB9A
SCHEMBL1342183 0.81 ALDH1A1 (0.51) LMNATP53MAPK1NPC1RAB9A
SCHEMBL9191760 0.81 ROCK1 (0.50) LMNATP53MAPK1NPC1RAB9A
SCHEMBL10625689 0.81 POLB (0.51) LMNATP53MAPK1ROCK1L3MBTL1
SCHEMBL10621418 0.81 ROCK1 (0.52) LMNAROCK1ADRA2CKMT2AALDH1A1
SCHEMBL9193973 0.81 ROCK1 (0.50) LMNATP53MAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US disclosed
WO-2021094974-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. (US) 2021-05-20 WO disclosed
WO-2021094974-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. (US) 2021-05-20 WO disclosed
EP-3821947-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2021-05-19 EP disclosed
EP-3821947-A1 HETEROCYCLIC TRPML1 AGONISTS Libra Therapeutics, Inc. (US) 2021-05-19 EP disclosed
US-5536717-A ANTIDEPRESSANTS, ANALGESICS HOECHST MARION ROUSSEL INC. (US) 1996-07-16 US disclosed
US-4764616-A ANALGESIC, ANTIPHYCHOTIC HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-16 US disclosed
US-4761412-A Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the treatment of psychoses HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-02 US disclosed
US-4761411-A Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-08-02 US disclosed
US-4723007-A ANALGESICS, ANTIPSYCHOTIC AGENTS; INTERMEDIATES FOR PROCESSING HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4723003-A ANTIPSYCHOTIC AGENTS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-02-02 US disclosed
US-4663453-A Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-05-05 US disclosed
EP-0129692-A2 Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-01-02 EP disclosed
US-4192874-A Substituted 1,2,6,7-tetrahydroindolo[1,7-ab][1,5]benzodiazepines AMERICAN HOECHST CORPORATION (US) 1980-03-11 US disclosed
US-4186199-A Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines AMERICAN HOECHST CORPORATION (US) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS TRPM7, TRPM2, TRPM5 LMNA 2253/4885TP53 3950/4885MAPK1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.